Zydus Lifesciences rises as its NCE Usnoflast receives Fast Track Designation from USFDA
Zydus Lifesciences is currently trading at Rs. 925.25, up by 7.20 points or 0.78% from its previous closing of Rs. 918.05 on the BSE.
The scrip opened at Rs. 922.05 and has touched a high and low of Rs. 926.65 and Rs. 917.40 respectively. So far 19895 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 926.65 and Rs. 880.20 respectively. The current market cap of the company is Rs. 93101.80 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences’ NCE (novel Chemical Entity) Usnoflast has received ‘Fast Track Designation’ from the United States Food and Drug Administration (USFDA). Usnoflast is a novel oral NLRP3 inhibitor for the treatment of amyotrophic lateral sclerosis (ALS).
A drug that receives Fast Track Designation from the USFDA is eligible for accelerated approval and priority review, if the relevant criteria are met. The purpose of Fast Track Designation is to get important new drugs to the patients faster.
Zydus Lifesciences is an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
